Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis
Information source: Olive View-UCLA Education & Research Institute
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pyelonephritis
Intervention: No intervention (Other)
Phase: N/A
Status: Completed
Sponsored by: Olive View-UCLA Education & Research Institute
Summary
Pyelonephritis is a serious infection that manifests with fever, back pain, nausea, and
vomiting. In the U. S., it is estimated that there are 20 cases of pyelonephritis per 10,000
annually, with the highest incidence in young women. Escherichia coli (E. coli) causes over
80% of these infections. Over the last two decades, E. coli resistance has emerged to
commonly prescribed antimicrobials, such as ampicillin and trimethoprim-sulfamethoxazole
(TMP/SMX). Most recently, resistance to fluoroquinolones and strains producing
extended-spectrum beta-lactamases (ESBL) have been observed. In order to better understand
the evolution and current state of antibiotic resistance among E. coli urinary tract
isolates so as to better inform treatment decisions, the investigators propose to conduct an
investigation to: a) determine the prevalence of antimicrobial resistance among E. coli
causing acute pyelonephritis in various patient groups, and specifically healthy
community-dwellers with uncomplicated infections, b) determine the specific prevalence of
fluoroquinolone-resistance and ESBL-producing E. coli, and c) determine potential risk
factors for fluoroquinolone and ESBL-producing E. coli infections.
Clinical Details
Official title: Surveillance and Risk Factor Analysis of Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis in the United States
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: Prevalence of antimicrobial resistant E. coli in the U.S.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients > 18 years of age with flank pain and/or costovertebral angle tenderness
- documented temperature in the emergency department of ≥38°C/100. 4°F by any method of
measurement,
- documented temperature in the emergency department of ≥38°C/100. 4°F by any method of
measurement,
Exclusion Criteria:
- complicated pyelonephritis
Locations and Contacts
Olive View-UCLA Medical Center, Sylmar, California 91342, United States
Additional Information
Starting date: July 2013
Last updated: April 23, 2015
|